Region-wise, TPL's India business grew by five per cent YoY to Rs 871 crore in the third quarter ended December 31, 2019. After adjusting for one off item, the growth stood at 8.5 per cent, the company stated. TPL added that the one off pertained to integration of Torrent and Unichem stockist in Q3 FY19 and the base impact of products discontinued in the last year.
Its US revenues took a beating with a 22 per cent fall in Q3 of FY20 at Rs 381 crore even as three abbreviated new drug applications (ANDAs) were filed during the quarter, taking the tally to 45 ANDAs pending approval and six tentative approvals being received.
TPL's Germany revenues too fell by 18 per cent on a YoY basis in Q3 of FY20 at Rs 219 crore while that for Brazil grew by 12 per cent YoY to Rs 189 crore. The company's research and development (R&D) spending stood at Rs 110 crore in Q3 FY20 against Rs 135 crore in Q3 FY19.
A Rs 7600 crore flagship company of Torrent Group, Torrent Pharmaceuticals
Ltd. has eight manufacturing facilities, including seven in India and one in the US, of which five are USFDA